NeuroPace IncNPCE
Price$13.15Intrinsic value$12.574% below price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $107M+33.9% YoYTTM through 30 Jun 2026
Net Income -$19.1MTTM through 30 Jun 2026
Free Cash Flow -$11.6MTTM through 30 Jun 2026

Margins

Current
Gross Margin81.8%
EBITDA Margin-11.0%
Operating Margin-25.2%
Net Margin-17.9%

Returns

-149.2%ROE
-21.8%ROA

Balance Sheet Health

Debt / Equity4.08x
Current Ratio4.11x
Net Debt$5M
Cash & Equivalents$12.5M

Quality Metrics

Altman Z-Score-3.06
Piotroski F-Score4 / 9
FCF Margin-10.9%
Earnings-Beat Rate66.7%

Multi-Year Trend

Revenue
'20'21'22'23'24'25
FY2025: $100M
Diluted EPS-$0.57TTM
'20'21'22'23'24'25
FY2025: $-0.66

Dividend

No dividend

Capital Allocation

R&D Spend$27.7M
Capex Intensity0.3%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.